Substituted thieno[2,3-d]pyrimidines as hsp90 inhibitors

Abstract

Compounds of formula (1) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment of inter alia, Cancer: wherein Ris a group of formula —(Ar)-(Alk)-(Z)-(Alk 2)-Q wherein Aris an optionally substituted aryl or heteroaryl radical, Alk' and Alk 2 are optionally substituted divalent C-Calkylene or C-Calkenylene radicals, m, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C═O)—, —(C═S)—, —SO—, —C(═O)O—, —C(═O)NR—, —C(═S)NR—, —SONR—, —NRC(═O)_, —NRSO- or —NR—wherein Ris hydrogen or C-Calkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; Ris hydrogen, an optional substituent, or an optionally substituted (C-C)alkyl, aryl or heteroaryl radical; and Ris a carboxylic ester, carboxamide or sulfonamide group.